Description: RenalytixAI is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Our goal is to lower healthcare costs and improve patient quality of life by transforming the paradigm for kidney disease risk assessment and clinical management through our KidneyIntelX platform.
Home Page: renalytix.com
RNLX Technical Analysis
1460 Broadway
New York,
NY
10036
United States
Phone:
646 397 3970
Officers
| Name | Title |
|---|---|
| Mr. James R. McCullough M.B.A. | CEO & Exec. Director |
| Mr. Fergus Fleming | CTO & Exec. Director |
| Mr. Thomas H. McLain CPA, M.B.A | Pres |
| Mr. Oliver James Sterling III | Chief Financial Officer |
| Ms. Andria Parks-Herrera | VP of Marketing |
| Ms. Jean M. Casner | Sr. VP & Chief HR Officer |
| Mr. Baljit Singh | Head of Clinical Operations |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer |
| Mr. Salim Hamir F.C.A. | Company Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Technology |
| GIC Sub-Industry: | Health Care Technology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5969 |
| Price-to-Sales TTM: | 21.2609 |
| IPO Date: | 2020-07-17 |
| Fiscal Year End: | June |
| Full Time Employees: | 102 |